About Ocular Therapeutix
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Bedford, MA
- Founded
- 2006
- Company type
- Public Company
- Company profile name
- Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational candidate for retinal disease, based on its proprietary ELUTYX™ technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).
Specialties
- Retina
- Retinal Disease
- Wet AMD
- NPDR
- DME
- Anti-VEGF
- Tyrosine Kinase Inhibitors
- Ocular Drug Delivery
- Sustained Delivery
- Ophthalmic Therapies
- and Ophthalmology
Company locations
15 Crosby Drive, Bedford, MA 01730, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Medical Device
- Biotechnology
- Pharmaceutical
On LinkedIn
- Followers
- 34,365
- People linked to this company
- 348
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
1,186,510,836 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.